T1574

Etoricoxib (MK-663) is a synthetic, nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic, and potential antineoplastic properties. Etoricoxib specifically binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in inhibition of the conversion of arachidonic acid into prostaglandins. Inhibition of COX-2 may induce apoptosis and inhibit tumor cell proliferation and angiogenesis.

Levetimide is a potent and stereoselective [3H](+)pentazocine binding inhibitor (Ki: 2.2 nM).

Levobunolol hydrochloride is a non-selective blocker of β-adrenergic receptor and can be used in studies about managing glaucoma and superior oblique myokymia.

Levomepromazine (Methotrimeprazine) is an orally active aliphatic phenothiazine antipsychotic compound and a Ca2+ release inducer, exhibiting antiviral, anti-inflammatory, neuroprotective, analgesic, and anti-nociceptive activities. Levomepromazine inhibits dopaminergic, cholinergic, serotoninergic, and histaminergic receptors, and is used for research in neurodegenerative diseases.

Lexacalcitol is over 100 times more active than 1alpha,25-dihydroxyvitamin D3 [1alpha,25-(OH)2D3], as judged by in vitro antiproliferative and cell differentiating assays.

Lexibulin 2Hcl is an effective tubulin polymerization inhibitor (IC50: 10-100 nM in cancer cell lines). It also has potent cytotoxic and vascular disrupting activity in vitro and in vivo.

Lexithromycin is an erythromycin A derivative. It has antibacterial activity.

LG100754 (UVI 2112) is an insulin sensitizer that functions through RXR. LG100754 is an RXR dimer modulator. LG100754 acts as an RXR: RXR homodimer antagonist, but functions as an agonist towards RXR: PPARα and RXR: PPARγ heterodimers.